	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	106.86	33.18	14.90	19.03	20.99	28.65	51.01	82.49	53.32	68.52	114.23	139.60	154.37	198.32	235.47	237.21
Cost of Operating Revenue	83.67	28.09	7.73	9.97	18.78	22.32	31.43	59.20	37.93	46.22	77.50	94.26	100.20	132.54	151.16	150.09
Gross Profit	23.19	5.09	7.17	9.06	2.21	6.33	19.58	23.29	15.39	22.30	36.73	45.33	54.17	65.78	84.32	87.13
Gross Margin	21.7	15.3	48.1	47.6	10.5	22.1	38.4	28.2	28.9	32.5	32.2	32.5	35.1	33.2	35.8	36.7
Total Operating Expenses	113.48	38.15	20.09	22.27	35.40	39.11	47.77	76.54	55.03	65.29	105.61	125.58	133.41	169.36	202.50	204.82
Operating Profit	-6.62	-4.97	-5.19	-3.25	-14.41	-10.45	3.24	5.95	-1.71	3.23	8.62	14.02	20.97	28.96	32.97	32.40
Operating Margin	-6.2	-15.0	-34.9	-17.1	-68.7	-36.5	6.3	7.2	-3.2	4.7	7.5	10.0	13.6	14.6	14.0	13.7
Financing Income/(Expense) - Net	-1.91	8.82	6.25	-	-	-	-	2.56	3.15	1.71	0.73	-2.59	-2.11	4.73	5.05	-4.91
Profit before Taxes	99.00	3.28	1.06	-0.95	-11.63	-9.32	6.11	8.59	1.61	5.12	9.61	12.01	19.35	34.47	38.65	39.07
Income Taxes	21.05	-0.01	-0.11	-0.66	-0.44	-0.43	0.96	4.76	0.77	1.35	3.40	3.73	5.78	9.53	9.15	9.86
Profit after Tax	77.95	3.28	1.18	-0.29	-11.19	-8.89	5.15	3.83	0.84	3.67	7.37	10.45	14.60	26.70	30.17	30.05
PAT Margin	72.9	9.9	7.9	-1.5	-53.3	-31.0	10.1	4.6	1.6	5.4	6.4	7.5	9.5	13.5	12.8	12.7
EPS - Basic - ex Extraordinary Items	28.82	1.21	0.44	-0.11	-4.14	-3.29	1.90	1.28	0.27	1.16	2.32	3.28	4.49	8.12	8.91	8.72
EPS - Diluted - ex Extraordinary Items	26.26	1.21	0.44	-0.11	-4.14	-3.29	1.79	1.28	0.27	1.16	2.32	3.28	4.49	8.12	8.91	8.72
EBIT	-6.62	-4.97	-5.19	-3.25	-14.41	-10.45	3.24	5.95	-1.71	3.23	8.62	14.02	20.97	28.96	32.97	32.40
EBITDA	-1.79	-3.74	-3.75	-1.39	-4.37	-0.70	5.28	8.00	0.29	5.22	11.09	17.57	24.32	32.07	36.59	36.27
EBITDA Margin	-1.7	-11.3	-25.2	-7.3	-20.8	-2.4	10.3	9.7	0.5	7.6	9.7	12.6	15.8	16.2	15.5	15.3

Balance Sheet

Abridged

Understanding Balance Sheet

Kilitch Drugs (India) Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	164.52	126.16	95.85	46.72	45.82	48.57	62.98	64.88	55.79	80.36	114.10	126.40	145.99	173.92	222.20
Long-Term Investments	4.41	0.72	1.20	47.16	25.82	27.80	26.79	25.02	24.59	25.65	26.07	22.68	22.85	22.86	22.89
Property Plant & Equipment - Net	8.37	8.75	9.27	9.34	8.68	8.67	10.98	28.76	38.33	73.38	46.40	47.36	48.12	92.82	188.72
Total Non-Current Assets	13.13	10.71	33.22	80.01	70.18	64.32	64.69	78.78	87.05	122.81	95.74	93.12	94.07	138.87	235.55
Total Assets	177.65	136.87	129.07	126.73	116.00	112.89	127.67	143.66	142.83	203.18	209.85	219.52	240.06	312.78	457.75
Total Current Liabilities	61.25	17.56	8.69	6.85	8.25	11.69	14.92	20.09	21.97	73.32	69.28	68.87	64.22	84.31	121.60
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	27.77	58.60
Total Non-Current Liabilities	0.63	0.25	0.15	0.00	-	-	-	0.41	0.39	0.38	0.28	0.07	0.17	28.02	59.28
Total Liabilities	61.88	17.81	8.84	6.85	8.25	11.69	14.92	20.51	22.36	73.70	69.55	68.94	64.39	112.33	180.88
Total Shareholders' Equity	115.77	119.05	120.23	119.88	107.75	101.20	112.03	121.06	118.25	127.13	139.09	151.60	176.29	202.33	279.65
Minority Interest	-	-	-	-	-	-	0.73	2.10	2.22	2.35	1.21	-1.02	-0.62	-1.87	-2.79
Total Equity	115.77	119.05	120.23	119.88	107.75	101.20	112.76	123.15	120.47	129.48	140.29	150.58	175.67	200.46	276.87
Total Liabilities & Equity	177.65	136.87	129.07	126.73	116.00	112.89	127.67	143.66	142.83	203.18	209.85	219.52	240.06	312.78	457.75

Cash Flow

Abridged

Understanding Cash Flow Statement

Kilitch Drugs (India) Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	-2.84	5.31	-1.88	3.09	-1.46	2.59	8.40	6.68	-2.31	6.38	16.85	12.86	18.64	23.16	31.05
Working Capital - Increase/(Decrease)	-28.46	4.34	-27.78	-8.70	19.71	-1.08	-6.47	-5.99	6.33	38.75	-5.19	-14.88	-24.31	-9.63	-12.11
Net CF from Operating Activities	-31.31	9.65	-29.66	-5.61	18.25	1.50	1.93	0.69	4.02	45.13	11.66	-2.02	-5.67	13.53	18.94
Capital Expenditures - Net	27.28	1.63	1.90	2.39	43.08	1.33	3.49	19.02	10.50	36.30	8.20	3.81	6.45	46.87	99.51
Net CF from Investing Activities	41.99	28.67	70.57	-33.20	-20.59	-1.92	-4.72	-14.38	-10.73	-37.80	-15.50	7.61	-9.95	-40.98	-100.98
Dividends Paid - Cash - Total	1.49	46.14	-	0.02	0.07	0.04	0.04	0.95	1.79	-	1.20	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	2.95	7.05	0.08	0.06	0.09	2.50	3.86	-	48.73
Debt - LT & ST - Issuance/(Retirement) - Total	-6.88	-0.89	-	-	0.19	-	-	8.53	3.16	2.19	2.50	1.76	9.45	17.78	39.29
Net Cash Flow from Financing Activities	-8.37	-47.02	-	-0.06	0.11	-0.04	5.27	16.86	1.57	2.37	1.40	4.20	14.74	18.28	88.01
Free Cash Flow to Equity	-65.46	7.14	-31.56	-8.00	-24.64	0.18	-1.56	-9.80	-3.33	11.03	5.96	-4.07	-2.67	-15.56	-41.28
Free Operating CF net dividend	-60.08	-38.11	-31.56	-8.02	-24.89	0.14	-1.60	-19.28	-8.27	8.83	2.26	-5.84	-12.12	-33.34	-80.56
Free Operating CF	-58.58	8.02	-31.56	-8.00	-24.82	0.18	-1.56	-18.33	-6.48	8.83	3.46	-5.84	-12.12	-33.34	-80.56

Business Segment Analysis

FY End:

Mar 25

Kilitch Drugs (India) Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 46.87 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 198.32 Cr

Assets

Pharmaceuticals (100.0%)₹ 312.78 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 28.96 Cr

Regional Segment Analysis

Kilitch Drugs (India) Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Kilitch Drugs (India) Ltd.

Historical Segment Analysis

Track how Kilitch Drugs (India) Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31
Pharmaceuticals	10	36	8	4	6	47

Frequently Asked Questions

What is the revenue of Kilitch Drugs (India) Ltd.?

The latest trailing twelve month revenue of Kilitch Drugs (India) Ltd. is ₹ 237.21 Cr, reflecting a 1-year growth of 14.04% and a 3-year CAGR of 18.46%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Kilitch Drugs (India) Ltd.?

The latest trailing twelve month net profit (PAT) of Kilitch Drugs (India) Ltd. is ₹ 29.11 Cr, with a 3-year earnings CAGR of 33.35%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Kilitch Drugs (India) Ltd.?

The trailing twelve month EBITDA of Kilitch Drugs (India) Ltd. is approximately ₹ 32.40 Cr (based on an operating margin of 13.66%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Kilitch Drugs (India) Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Kilitch Drugs (India) Ltd. is 8.72. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Kilitch Drugs (India) Ltd.?

The debt-to-equity ratio of Kilitch Drugs (India) Ltd. stands at 0.32. The interest coverage ratio is 6.60x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Kilitch Drugs (India) Ltd.?

The estimated book value per share of Kilitch Drugs (India) Ltd. is 79.99 (derived from a P/B ratio of 2.16 and market price of ₹ 172.40), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Kilitch Drugs (India) Ltd.?

The trailing twelve month operating cash flow of Kilitch Drugs (India) Ltd. is ₹ 18.94 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Kilitch Drugs (India) Ltd. report consolidated or standalone financials?

Kilitch Drugs (India) Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.